Venture capital continues to flow into biopharma in Q3 2026, favoring later-stage and AI-driven companies

Venture capital funding into biopharma topped $16 billion in the first half of 2026 and kept rising in the third quarter, according to industry sources.

Investors remain selective, directing money toward later‑stage, more de‑risked assets and companies that use artificial‑intelligence platforms, said Dan Greaney of J.P. Morgan.

Experts noted that while overall deal activity is constrained, a small number of firms are receiving larger capital infusions, leading to a concentration of funding among a limited group of companies.